| Pharmaceutical Information |
| Drug Name |
Polymyxin b |
| Drug ID |
BADD_D01794 |
| Description |
Polymyxin B was discovered in the 1940s[A176429]. They are basic polypeptides of about eight amino acids and have cationic detergent action on cell membranes[A176426]. Polymyxin B is used for infections with gram-negative organisms, but may be neurotoxic and nephrotoxic[A176426,FDA Label]. All gram-positive bacteria, fungi, and the gram-negative cocci, are resistant[A176426]. It is appropriate for treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of _Pseudomonas aeruginosa_[FDA Label]. Polymyxin B has a narrow therapeutic index and so its use is limited and unlikely to be used first line[A176429]. |
| Indications and Usage |
Polymyxin B is indicated for the treatment of infections of the urinary tract, meninges, and blood stream, caused by susceptible strains of Pseudomonas aeruginosa[FDA Label]. |
| Marketing Status |
approved; vet_approved |
| ATC Code |
A07AA05; J01XB02; S01AA18; S02AA11; S03AA03 |
| DrugBank ID |
DB00781
|
| KEGG ID |
D01066
|
| MeSH ID |
D011112
|
| PubChem ID |
49800004
|
| TTD Drug ID |
D09OOV
|
| NDC Product Code |
55150-234; 39822-0166 |
| UNII |
J2VZ07J96K
|
| Synonyms |
Polymyxin B | Polymyxin B Sulfate | Aerosporin |
|
| Chemical Information |
| Molecular Formula |
C56H98N16O13 |
| CAS Registry Number |
1404-26-8 |
| SMILES |
CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)
C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)C(C)O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice..
|
|
|
